Key findings
- 111 of 203countries where cardiac rehabilitation was available (54.7%), from 80.7% of countries in Europe to 17.0% in Africa
- 1.66 millionpatients a year that programs worldwide had capacity for, against an estimated 20.3 million incident cases of ischemic heart disease
- 1.19risk ratio for total mortality, home-based versus center-based rehabilitation (95% confidence interval 0.65 to 2.16): no evidence of a difference across 24 randomized trials
- 80% vs 47%completion with a smartphone-based home care model versus traditional center-based rehabilitation in an Australian trial of 120 patients
Abstract
Cardiac rehabilitation reduces myocardial infarction and hospitalization after acute coronary syndromes, coronary revascularization, and heart failure, yet it remains one of the most underused therapies in cardiovascular medicine worldwide. Only about half of the world’s countries offer any cardiac rehabilitation, global program capacity is sufficient for roughly one in every twelve eligible patients, and participation among eligible patients rarely exceeds one third in high-income countries and is far lower in low- and middle-income countries. Because distance, transportation, work obligations, and program capacity are the dominant barriers, remote delivery has emerged as the most scalable response. The aim of this narrative review is to critically appraise two closely related approaches to closing this participation gap: home-based, hybrid, and telehealth-delivered cardiac rehabilitation, and wearable and connected-device monitoring that extends clinician oversight into the home. Randomized trials and meta-analyses from North America, Europe, Australasia, and Asia indicate that home-based and telehealth-delivered programs produce gains in exercise capacity, quality of life, and risk-factor control similar to those of center-based programs, with comparable safety and frequently higher completion. Wearable sensors reliably capture heart rate, rhythm, and activity and can increase physical activity, but evidence that continuous monitoring improves hard outcomes in rehabilitation populations is limited. Newer exercise prescriptions, immersive technologies, and connected exercise devices are promising when delivered through these platforms, although their cardiac-specific evidence remains early. Reimbursement, data interoperability, digital literacy, and safety escalation pathways, all of which differ substantially between health systems, are the principal barriers to adoption. Technology-enabled rehabilitation should be integrated within the established core components of cardiac rehabilitation and evaluated in diverse populations, including those in low-resource settings.
Introduction
Cardiovascular disease remains the leading cause of death worldwide, accounting for an estimated 20.5 million deaths in 2021, the large majority of which occurred in low- and middle-income countries.1 Ischemic heart disease alone produces more than 20 million incident cases each year that would qualify for secondary prevention,2 and a growing population of survivors of myocardial infarction, coronary revascularization, and heart failure hospitalization now lives with chronic disease that requires structured, long-term risk reduction.
Cardiac rehabilitation is one of the most consistently underused, guideline-endorsed therapies in cardiovascular medicine. Structured, supervised exercise training combined with risk-factor modification, psychosocial support, and patient education reduces recurrent myocardial infarction, lowers rehospitalization, and improves quality of life after myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, and heart failure decompensation.3 The most recent Cochrane review, which included 85 randomized trials and 23,430 patients with coronary heart disease, found that exercise-based rehabilitation reduced myocardial infarction (risk ratio 0.72, 95% confidence interval 0.55 to 0.93) and all-cause hospitalization (risk ratio 0.58, 95% confidence interval 0.43 to 0.77), although the reduction in all-cause mortality in contemporary trials did not reach statistical significance (risk ratio 0.87, 95% confidence interval 0.73 to 1.04).4,5 The 2024 update to the American Heart Association and American Association of Cardiovascular and Pulmonary Rehabilitation Core Components statement reaffirmed medical evaluation, exercise training, cardiovascular risk-factor management, psychosocial management, and patient education as the pillars of a program, while explicitly broadening the framework to accommodate technology-enabled, home-based, and hybrid delivery models alongside traditional center-based care.3 The European Association of Preventive Cardiology has taken a similar position for European programs.6
That broadening reflects an uncomfortable reality: guideline-concordant referral does not translate into guideline-concordant participation. An analysis of Medicare beneficiaries in the United States found that only 26.4% of those eligible after a qualifying cardiac event enrolled in cardiac rehabilitation within 90 days of discharge, with median risk-standardized hospital enrollment of only 22% and a ten-fold range across hospitals, from 3% at the 10th percentile to 42% at the 90th.7 Fewer than 1% of hospitals reached the commonly cited 70% enrollment target. Enrollment was strongly associated with the type of index event, patient age, income, geography, and smoking status, and was more strongly predicted by which hospital a patient was treated at than by clinical characteristics alone.7 A separate national analysis found that participation was only 19% among women and 10% among patients aged 85 years or older, and that only 27% of participants completed the recommended 36 or more sessions.8 Distance to a facility, transportation, work and caregiving obligations, and program capacity are recurring, modifiable barriers.9
The participation gap is not unique to the United States. A global audit by the International Council of Cardiovascular Prevention and Rehabilitation found that cardiac rehabilitation was available in only 111 of 203 countries (54.7%), ranging from 80.7% of countries in Europe to 17.0% in Africa, and that the 5,753 programs identified worldwide had capacity for approximately 1.66 million patients each year against an estimated 20.3 million incident cases of ischemic heart disease, or roughly one rehabilitation place for every 12 patients in need.2,10 Even where programs exist, participation is modest. In the fourth European Action on Secondary and Primary Prevention by Intervention to Reduce Events survey of 7,998 coronary patients in 24 European countries, only 51% were advised to attend cardiac rehabilitation, and only 41% of the entire cohort attended at least half of the prescribed sessions.11 In Japan, although 56.5% of surveyed hospitals offered outpatient cardiac rehabilitation, only 7.3% of patients with heart failure actually received it.12 In low- and middle-income countries, where the burden of cardiovascular disease is growing fastest, program availability is lowest, programs are concentrated in urban tertiary centers, and patients face the additional barriers of out-of-pocket cost, long travel distances, and a limited rehabilitation workforce.2,9,10
The coronavirus disease 2019 pandemic exposed the fragility of a model that depends entirely on in-person attendance. An international survey of rehabilitation programs conducted during the pandemic found that most suspended in-person services, and that many of those able to continue did so by rapidly adopting telephone, video, and application-based delivery, frequently without established protocols or reimbursement.13 Professional societies in the United States and Europe have since endorsed home-based and telehealth-delivered models as legitimate options for appropriately selected patients.3,14,15 Against this backdrop, the current wave of digital and device-based cardiac rehabilitation is best viewed as a direct response to a well-documented and global access failure.
Aim and Scope
Because the literature on technology in cardiac rehabilitation has grown rapidly, a review that attempts to cover every innovation risks covering none of them in adequate depth. The aim of this narrative review is therefore to critically appraise the evidence for two closely related strategies intended to close the cardiac rehabilitation participation gap: first, remote delivery of cardiac rehabilitation through home-based, hybrid, and telehealth programs; and second, remote monitoring of patients during rehabilitation using wearable sensors and connected devices. For each, we examine comparative effectiveness against center-based care, the consistency of findings across high-income and low- and middle-income health systems, safety, and the populations in which evidence is lacking. Newer exercise prescriptions, immersive technologies, and connected exercise devices are discussed only as content delivered through, or data captured by, these two platforms. Pharmacologic secondary prevention, inpatient rehabilitation, and the psychosocial and educational components of rehabilitation are beyond the scope of this review, except where they are delivered remotely.
This review draws on randomized trials, systematic reviews and meta-analyses, and professional society statements published in English, with emphasis on evidence published from 2014 through 2026 and on studies conducted outside, as well as within, the United States. Where meta-analytic evidence exists, it is presented first, followed by individual trials selected because they illustrate a distinct delivery model or health-system setting.
Remote Delivery: Home-Based, Hybrid, and Telehealth Cardiac Rehabilitation
Definitions and delivery models
Terminology in this field is inconsistent, which complicates comparison across trials. In this review, home-based cardiac rehabilitation refers to a structured program in which most exercise sessions occur outside a rehabilitation facility, guided by a clinician through scheduled contact; telerehabilitation refers to home-based programs in which that contact, and often exercise monitoring, is delivered by telephone, videoconference, smartphone application, or wearable sensors; and hybrid rehabilitation refers to programs that combine an initial period of center-based sessions with subsequent home-based or remote sessions.14,16 Remote contact may be synchronous, with a clinician observing exercise in real time, or asynchronous, with exercise data uploaded and reviewed later. These distinctions matter because the degree of real-time supervision is likely to influence safety and the training intensity patients achieve more than the location of exercise itself.
Comparative effectiveness against center-based programs
The most robust comparative evidence comes from the 2023 Cochrane review of home-based versus center-based cardiac rehabilitation, which included 24 randomized trials and 3,046 participants after myocardial infarction or revascularization, or with heart failure.17 There was no evidence of a difference between settings in total mortality (risk ratio 1.19, 95% confidence interval 0.65 to 2.16) or exercise capacity (standardized mean difference −0.10, 95% confidence interval −0.24 to 0.04), and health-related quality of life and costs were broadly similar.17 However, the certainty of evidence was low to moderate, and most included trials enrolled lower-risk patients with coronary disease.
More recent evidence has focused specifically on telerehabilitation. A 2024 systematic review and meta-analysis of cardiac telerehabilitation models for coronary artery disease found that programs combining remote exercise prescription with real-time or near-real-time monitoring achieved improvements in exercise capacity, quality of life, and modifiable risk factors comparable to center-based programs, with the specific technological configuration (synchronous video versus asynchronous app-based coaching versus wearable-only monitoring) influencing adherence more than it influenced physiological outcomes.18 A 2025 systematic review and meta-analysis in The Lancet Digital Health of home-based cardiac rehabilitation delivered via mobile health technologies similarly reported that mobile health-supported programs produced meaningful gains in functional capacity and health-related quality of life relative to usual care, reinforcing home-based and hybrid delivery as a viable, and in some settings preferable, alternative to purely center-based programs, particularly for patients whose geography, mobility, or working hours preclude regular in-person attendance.19
Evidence across health systems
Because health-system context strongly influences who is referred, who enrolls, and what a program costs, findings from a single country cannot be assumed to generalize. European trials have tested remote models within systems that already offer publicly funded center-based rehabilitation. In the Netherlands, a randomized trial of 90 low-to-moderate risk patients found that home-based training guided by heart rate monitoring with remote coaching produced improvements in peak oxygen uptake similar to those of center-based training, at comparable cost.20 In Belgium, adding an internet-based, patient-specific telerehabilitation program with text-message support to conventional rehabilitation in 140 patients reduced cardiovascular rehospitalization over one year and was cost-effective.21 Of particular relevance to older patients, a multinational European randomized trial enrolled 179 patients aged 65 years or older who had declined center-based rehabilitation and found that a six-month, mobile-guided home program improved peak oxygen uptake compared with no rehabilitation, demonstrating that remote delivery can reach patients who would otherwise receive nothing.22
Trials from Australasia have focused on uptake and completion. In Australia, a randomized trial of 120 patients after myocardial infarction found that a smartphone-based home care model, incorporating activity monitoring, daily data upload, and weekly mentor consultation, increased uptake (80% versus 62%), adherence (94% versus 68%), and completion (80% versus 47%) compared with traditional center-based rehabilitation, with similar improvements in physiological outcomes.23 In New Zealand, a noninferiority trial of 162 patients with coronary heart disease found that real-time, remotely monitored exercise using a smartphone, a chest-worn sensor, and live clinician coaching was noninferior to center-based rehabilitation for maximal oxygen uptake at 12 weeks and was less expensive to deliver.24
Evidence from middle-income countries is more limited but increasingly important. In China, a randomized trial of 312 patients after percutaneous coronary intervention in Shanghai delivered rehabilitation and secondary prevention through a widely used social media platform, and improved functional capacity and risk-factor control compared with usual care, showing that remote delivery can be built on infrastructure patients already use every day.25 In India, one of the largest cardiac rehabilitation trials ever conducted randomized 3,959 patients after acute myocardial infarction at 24 centers to a culturally adapted, yoga-based program or enhanced usual care.26 Although the program did not significantly reduce major adverse cardiovascular events, it improved self-rated health and return to pre-infarction activities, and its low-cost, minimal-equipment design is well suited to delivery outside a hospital.26 Together, these trials suggest that the most effective remote model in any given country is the one adapted to its existing digital infrastructure, culture, and workforce.
In the United States, real-world data from an integrated health system support these trial findings. Among 2,556 patients in Kaiser Permanente Southern California, nearly half of whom chose home-based rehabilitation, those in the home-based program had a 21% lower risk of hospitalization at 12 months than those in center-based programs, with similar medication adherence and risk-factor control, and the benefit extended to patients classified as high risk.27 Because patients selected their own program, these observational findings are subject to confounding and cannot establish that home-based delivery caused fewer hospitalizations. However, they are reassuring with respect to safety and effectiveness in a diverse and medically complex population.
Heart failure and hybrid models
Patients with heart failure are among the least likely to participate in center-based programs and among the most likely to benefit from flexible delivery.12 A meta-analysis of home-based and hybrid programs in heart failure found that both improved exercise capacity and quality of life compared with usual care, and that gains in exercise capacity with hybrid programs, which begin with supervised center-based sessions before transitioning home, were at least as large as those with home-based programs alone.28 The hybrid model may be particularly useful for higher-risk patients, because the initial supervised phase allows exercise prescription and safety assessment before unsupervised training begins, and it is a practical compromise for health systems that lack the capacity to supervise every session in person.6,14
Safety
Safety is the most common concern raised about exercise without on-site supervision. A systematic review of home-based cardiac rehabilitation found that serious exercise-related adverse events were rare, although most trials excluded high-risk patients and few were powered to detect uncommon events.29 Current United States and European statements therefore recommend home-based and telehealth delivery primarily for low-to-moderate risk patients, with risk stratification, an initial exercise assessment, and a defined plan for symptom reporting before home exercise begins.6,14,15
These findings matter clinically because they establish telerehabilitation as a distinct delivery channel with its own advantages, most notably the ability to extend the reach of a finite pool of exercise physiologists and cardiac rehabilitation nurses to patients who would otherwise never enroll. They also raise an implementation question that the underlying trials only partly answer: what minimum degree of real-time clinician contact, physiologic monitoring, and safety oversight is required to preserve the mortality and readmission benefit historically attributed to supervised, center-based programs. This question motivates the continued interest in wearable sensors and connected exercise hardware capable of transmitting objective data back to a supervising clinician, as discussed below.
Remote Monitoring: Wearable Sensors and Connected Devices
Physiologic surveillance
Consumer and medical-grade wearables now provide continuous heart rate, rhythm, activity, and, increasingly, blood pressure and oxygenation data outside the clinic. A 2026 review in the European Heart Journal framed their cardiovascular applications across the full disease spectrum, from primordial prevention through chronic disease management.30 Several large studies illustrate the underlying capability. The Apple Heart Study screened 419,297 participants using photoplethysmography-based irregular-pulse notifications and found a positive predictive value of 84% for a subsequent diagnosis of atrial fibrillation among those who received an irregular-pulse alert, establishing population-scale feasibility for passive rhythm screening.31 The Fitbit Heart Study, which enrolled 455,699 participants, similarly found that an irregular rhythm notification had a positive predictive value of 98% for concurrent atrial fibrillation on a subsequent electrocardiogram patch.32 The Multisensor Non-invasive Remote Monitoring for Prediction of Heart Failure Exacerbation (LINK-HF) study demonstrated that a wearable patch coupled with a machine-learning analytics platform could detect impending heart failure decompensation with 76–88% sensitivity and 85% specificity, generating alerts a median of roughly 6.5 days before a clinical readmission event.33
Whether continuous monitoring improves outcomes, as distinct from detecting abnormalities, is a separate question. The strongest outcome evidence for remote physiologic surveillance comes from heart failure management in Germany, where the Telemedical Interventional Management in Heart Failure II trial randomized 1,538 patients to daily transmission of body weight, blood pressure, heart rhythm, oxygen saturation, and self-rated health status to a telemedical center staffed 24 hours a day, or to usual care.34 Remote management reduced the percentage of days lost to unplanned cardiovascular hospitalization or death (4.88% versus 6.64%) and reduced all-cause mortality (hazard ratio 0.70, 95% confidence interval 0.50 to 0.96).34 This trial is relevant to rehabilitation because it shows that the benefit of remote data depends on a staffed, protocolized response pathway, a lesson that applies equally to monitoring patients during home exercise.
Wearables within rehabilitation programs
Within rehabilitation programs, wearables serve three functions: prescribing and verifying exercise intensity by heart rate, quantifying daily physical activity, and sustaining engagement after formal rehabilitation ends. A meta-analysis of trials in the maintenance phase of cardiac rehabilitation found that wearable activity monitors combined with an exercise prescription or advice improved cardiorespiratory fitness compared with controls,35 and meta-analytic data cited in the European Heart Journal review found that wearable-supported exercise interventions produced a standardized mean difference of 0.72 in physical activity levels compared with usual care, an effect strengthened when paired with periodic clinician or coach contact rather than deployed as a standalone consumer device.30 However, wrist-worn photoplethysmography can be less accurate during high-intensity or irregular exercise and in atrial fibrillation, a limitation that matters when heart rate is used to prescribe or limit training intensity.30
The same review is appropriately measured about limitations: data formats remain incompatible across device manufacturers, few health systems have built the workflows or electronic health record integration needed to act on continuous data streams, clinically validated reference ranges for many wearable-derived metrics remain immature, and a digital divide in device ownership and connectivity risks concentrating the benefits of this technology among already-advantaged patients.30 For cardiac rehabilitation programs considering wearable integration, the evidence to date supports wearables as adjuncts that extend clinician visibility into home-based exercise sessions rather than as autonomous replacements for supervised care.
Exercise and Engagement Delivered Through Remote Platforms
High-intensity interval training
Remote delivery changes not only where patients exercise but also what they can be prescribed. A multicenter randomized controlled trial conducted across six United Kingdom cardiac rehabilitation centers randomized 382 patients with coronary artery disease to eight weeks of low-volume high-intensity interval training, ten one-minute intervals above 85% of maximal capacity separated by one-minute recovery periods, twice weekly, or to standard moderate-intensity continuous training.36 High-intensity interval training produced a significantly larger gain in peak oxygen uptake at eight weeks, 2.37 versus 1.32 mL·kg−1·min−1, an adjusted between-group difference of 1.04 mL·kg−1·min−1 (P = .002), with only one possibly related serious adverse event and dropout rates comparable to, or better than, those seen with conventional protocols.36 The between-group advantage narrowed by twelve months, suggesting the intervention accelerates early physiological adaptation more than it changes durable long-term fitness trajectories, but the trial nonetheless supports high-intensity interval training as a time-efficient, well-tolerated option for appropriately screened patients, and one that is readily adaptable to shorter, technology-supervised remote sessions. Because this trial was conducted under on-site supervision, whether high-intensity interval training can be delivered as safely at home with remote monitoring has not yet been established, and current home-based programs generally prescribe moderate-intensity training.14
Immersive and gamified modalities
Virtual reality and gamification apply technology to the adherence problem that limits both center-based and home-based cardiac rehabilitation. A 2025 systematic review and meta-analysis of twenty studies found that virtual-reality-based exercise interventions produced a significant improvement in six-minute walk distance relative to conventional training, a mean difference of 34.9 meters, alongside gains in quality-of-life measures, though the authors noted that evidence on adherence and patient satisfaction remained less consistent and that most included trials were small and heterogeneous in virtual reality platform.37 These modalities are best understood as complementary to, rather than competitive with, telehealth and wearable-based approaches: they principally target engagement and perceived exertion rather than physiologic monitoring or care coordination, and are increasingly bundled into connected exercise platforms rather than deployed as standalone interventions.
Connected exercise therapeutics
A distinct category of technology sits at the intersection of the trends above: internet-connected exercise devices that combine motorized, sensor-guided movement therapy with a clinician-facing telehealth portal. ROMTech’s PortableConnect system illustrates this category. The device is a motorized pedal unit that adapts in real time to a patient’s measured range of motion and can be operated in passive (motor-driven), active-assisted, active, and resistance modes; a wearable goniometric sensor tracks joint flexion and extension during each session, data are transmitted to a companion application that structures three to five daily sessions, and a clinician portal allows remote review of session adherence and objective range-of-motion metrics along with videoconferencing for follow-up.38 The system was developed and initially validated for post-orthopedic indications, and is the subject of an ongoing randomized comparison against traditional rehabilitation and continuous passive motion devices in patients with knee osteoarthritis and joint pain.39
Extension of this technology into cardiac rehabilitation is more recent and, at present, earlier in its evidence trajectory. ROMTech has entered a multi-year partnership with a cardiology practice network to deliver home-based cardiac rehabilitation services using the PortableConnect platform,40 and a prospective, single-cohort feasibility study, registered as NCT05972070, is currently recruiting approximately 500 adults with New York Heart Association class I–II symptoms who underwent coronary revascularization within the preceding 60 days.41 That twelve-week, thirty-six-session telemedicine-delivered protocol will assess session attendance and completion, the Duke Activity Status Index, the Short Physical Performance Battery, the Patient Health Questionnaire, and the Short Form-36, providing the first systematically collected feasibility, adherence, and patient-reported outcome data for this device specifically in a cardiac population.41
That evidence gap is not merely academic. A 2024 payer medical coverage policy addressing rehabilitative devices with remote monitoring or adjustment capabilities concluded that available published evidence was insufficient to establish an incremental health outcome benefit over standard rehabilitation alternatives and classified such devices as not medically necessary for coverage purposes pending stronger data.42 This is a useful corrective to enthusiasm about connected exercise hardware generally: the underlying engineering concept, objective range-of-motion feedback, adaptive resistance, and remote clinician visibility, is intuitively well matched to cardiac rehabilitation’s central challenge of extending supervised exercise beyond the walls of a rehabilitation center, but intuitive plausibility is not a substitute for outcome data in the population for which reimbursement and guideline endorsement are being sought. The ROMTech cardiac program is therefore best characterized as a promising, actively studied example of connected exercise therapeutics rather than as an established, evidence-backed standard of care.
Implementation Across Health Systems
Realizing the promise of these technologies at scale requires addressing barriers that are organizational and financial as much as clinical. Reimbursement policy has not kept pace with device innovation, as illustrated by the coverage determination above, and inconsistent payer recognition discourages health systems from investing in connected rehabilitation infrastructure even where clinical teams are enthusiastic.42 Interoperability remains limited: wearable and device-derived data rarely flow into the electronic health record in a structured, actionable form, and clinicians lack validated thresholds for many novel metrics.30 Digital equity is a further concern, since patients without reliable broadband, smartphone access, or digital literacy, often the same patients facing the geographic and socioeconomic barriers to center-based attendance described above, risk being excluded from remote-delivery models unless programs deliberately design for low-bandwidth and low-literacy use.9,30 Finally, safety oversight for home-based, technology-supervised exercise, particularly in patients recovering from acute myocardial infarction, requires clearly defined escalation pathways when remote monitoring detects an abnormal physiologic signal, a workflow question that most current trials are only beginning to formally characterize.
Reimbursement models differ substantially between countries and largely determine which remote models are adopted. In the United States, Medicare payment for cardiac rehabilitation has historically required direct physician supervision, and coverage of virtual and home-based sessions has depended on temporary regulatory flexibilities introduced during the pandemic, an uncertainty that discourages long-term investment.14,16 In several European countries, cardiac rehabilitation is funded through national health or social insurance systems, which has allowed telerehabilitation to be evaluated within publicly funded pathways, although national adoption remains uneven.6,15 In many low- and middle-income countries, cardiac rehabilitation is paid for out of pocket, and the absence of public funding is among the most frequently reported barriers to program development.2,10 In these settings, low-cost models that use existing mobile phone networks, text messaging, and community health workers may offer greater reach than device-intensive approaches designed for high-income markets.
Remote delivery also changes who participates. Women, older adults, rural residents, and patients from racial and ethnic minority groups are consistently underrepresented in center-based programs,8,9 and early evidence suggests remote models can increase participation and completion, as shown by the higher completion among home-based participants in Australia and the United States.23,27 Unfortunately, the same groups are often less likely to own a smartphone, have reliable broadband, or feel confident using digital tools. Remote programs can therefore narrow or widen disparities, depending on whether they also offer low-technology options such as telephone-based coaching.
Research Priorities
Several questions should be answered before technology-enabled rehabilitation becomes a default option. First, most trials enrolled low-to-moderate risk patients with coronary disease, and adequately powered trials in older, frail, and heart failure populations, and in patients with recent acute myocardial infarction, are needed.16,17 Second, few remote-delivery trials were powered for mortality or hospitalization, so the effect of remote programs on these outcomes is inferred largely from center-based trials and observational data. Third, the minimum effective amount of real-time supervision, and the specific monitoring parameters that should trigger clinician escalation, have not been defined. Fourth, evidence from Africa, South America, South Asia, and the Middle East remains sparse, and trials designed for these settings, using locally available technology and workforce, should be prioritized over extrapolation from high-income countries.2,10 Finally, standardized reporting of delivery model components, including the mode, frequency, and synchronicity of clinician contact, would allow future meta-analyses to identify which components drive benefit.16,18
Conclusion
Cardiac rehabilitation stands at a genuine inflection point. The clinical case for the therapy has never been stronger, yet participation worldwide remains a fraction of what guidelines recommend. Home-based, hybrid, and telehealth-delivered programs, supported by wearable and connected-device monitoring, collectively represent a coherent and increasingly evidence-based response to that gap in high-income and low- and middle-income countries alike. Each modality is supported by a different depth of evidence, from mature meta-analytic data for home-based rehabilitation and telerehabilitation to early-stage feasibility work for cardiac-specific connected exercise hardware, and clinicians and health systems should calibrate enthusiasm accordingly. The most productive path forward integrates these tools within, rather than instead of, the established core components framework, pairs each new technology with cardiac-population-specific outcome trials before broad adoption, includes patients and health systems outside high-income countries in that research, and treats reimbursement policy, data interoperability, and digital equity as first-order implementation problems rather than afterthoughts. Done deliberately, this convergence of digital health and connected exercise engineering offers a credible route to closing one of cardiovascular medicine’s most persistent and consequential care gaps.
Declarations
- Declarations
- The author declares that he own stock in ROM-Tech.
- Conflicts of Interest
- The author declares no conflicts of interest relevant to this article.
- Funding Statement
- The author received no specific funding for this work.
References
- World Heart Federation. World Heart Report 2023: Confronting the World’s Number One Killer. Geneva, Switzerland: World Heart Federation; 2023.
- Turk-Adawi K, Supervia M, Lopez-Jimenez F, et al. Cardiac Rehabilitation Availability and Density around the Globe. EClinicalMedicine. 2019;13:31-45.
- Brown TM, Pack QR, Aberegg E, et al. Core Components of Cardiac Rehabilitation Programs: 2024 Update: A Scientific Statement From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2024;150(19):e328-e347.
- Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;11(11):CD001800.
- Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol. 2022;19(3):180-194.
- Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2021;28(5):460-495.
- Pack QR, Keys T, Priya A, Pekow PS, Keteyian SJ, Thompson MP, D’Aunno T, Lindenauer PK, Lagu T. Is 70% Achievable? Hospital-Level Variation in Rates of Cardiac Rehabilitation Use Among Medicare Beneficiaries. JACC Adv. 2024;3:101275.
- Ritchey MD, Maresh S, McNeely J, et al. Tracking Cardiac Rehabilitation Participation and Completion Among Medicare Beneficiaries to Inform the Efforts of a National Initiative. Circ Cardiovasc Qual Outcomes. 2020;13(1):e005902.
- Iyngkaran P, Appuhamilage PY, Patabandige GS, Peru Kandage PSS, Usmani W, Hanna F. Barriers to Cardiac Rehabilitation among Patients Diagnosed with Cardiovascular Diseases—A Scoping Review. Int J Environ Res Public Health. 2024;21(3):339.
- Grace SL, Taylor RS, Gaalema DE, Redfern J, Kotseva K, Ghisi GLM. Cardiac Rehabilitation: A Global Perspective on Where We Have Come and Where We Must Go. JACC Adv. 2023;2(5):100412.
- Kotseva K, Wood D, De Bacquer D; EUROASPIRE investigators. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. Eur J Prev Cardiol. 2018;25(12):1242-1251.
- Kamiya K, Yamamoto T, Tsuchihashi-Makaya M, et al. Nationwide Survey of Multidisciplinary Care and Cardiac Rehabilitation for Patients With Heart Failure in Japan: An Analysis of the AMED-CHF Study. Circ J. 2019;83(7):1546-1552.
- Ghisi GLM, Xu Z, Liu X, et al. Impacts of the COVID-19 Pandemic on Cardiac Rehabilitation Delivery around the World. Glob Heart. 2021;16(1):43.
- Thomas RJ, Beatty AL, Beckie TM, et al. Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019;140(1):e69-e89.
- Scherrenberg M, Wilhelm M, Hansen D, et al. The future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic from the secondary prevention and rehabilitation section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2021;28(5):524-540.
- Beatty AL, Beckie TM, Dodson J, et al. A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities. Circulation. 2023;147(3):254-266.
- McDonagh STJ, Dalal H, Moore S, Clark CE, Dean SG, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023;10(10):CD007130.
- Pagliari C, Isernia S, Rapisarda L, Borgnis F, Lazzeroni D, Bini M, Geroldi S, Baglio F, Brambilla L. Different Models of Cardiac Telerehabilitation for People with Coronary Artery Disease: Features and Effectiveness: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(12):3396.
- Li L, Kitsiou S, Ozemek C, Ringeval M, Paré G, Wagner G. Effectiveness of home-based cardiac rehabilitation interventions delivered via mHealth technologies: a systematic review and meta-analysis. Lancet Digit Health. 2025. doi:10.1016/S2589-7500(25)00012-3
- Kraal JJ, Van den Akker-Van Marle ME, Abu-Hanna A, Stut W, Peek N, Kemps HM. Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: Results of the FIT@Home study. Eur J Prev Cardiol. 2017;24(12):1260-1273.
- Frederix I, Hansen D, Coninx K, et al. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis. Eur J Prev Cardiol. 2016;23(7):674-682.
- Snoek JA, Prescott EI, van der Velde AE, et al. Effectiveness of Home-Based Mobile Guided Cardiac Rehabilitation as Alternative Strategy for Nonparticipation in Clinic-Based Cardiac Rehabilitation Among Elderly Patients in Europe: A Randomized Clinical Trial. JAMA Cardiol. 2021;6(4):463-468.
- Varnfield M, Karunanithi M, Lee CK, et al. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. Heart. 2014;100(22):1770-1779.
- Maddison R, Rawstorn JC, Stewart RAH, et al. Effects and costs of real-time cardiac telerehabilitation: randomised controlled non-inferiority trial. Heart. 2019;105(2):122-129.
- Dorje T, Zhao G, Tso K, et al. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. 2019;1(7):e363-e374.
- Prabhakaran D, Chandrasekaran AM, Singh K, et al. Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction: A Randomized Trial. J Am Coll Cardiol. 2020;75(13):1551-1561.
- Nkonde-Price C, Reynolds K, Najem M, et al. Comparison of Home-Based vs Center-Based Cardiac Rehabilitation in Hospitalization, Medication Adherence, and Risk Factor Control Among Patients With Cardiovascular Disease. JAMA Netw Open. 2022;5(8):e2228720.
- Imran HM, Baig M, Erqou S, et al. Home-Based Cardiac Rehabilitation Alone and Hybrid With Center-Based Cardiac Rehabilitation in Heart Failure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019;8(16):e012779.
- Stefanakis M, Batalik L, Antoniou V, Pepera G. Safety of home-based cardiac rehabilitation: A systematic review. Heart Lung. 2022;55:117-126.
- Hughes AM, Taylor DJ, Morris PD, Brittain EL. Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention. Eur Heart J. 2026;47(18):2130-2145.
- Perez MV, Mahaffey KW, Hedlin H, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019;381(20):1909-1917.
- Lubitz SA, Faranesh AZ, Selvaggi C, et al. Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study. Circulation. 2022;146(19):1415-1424.
- Stehlik J, Schmalfuss C, Bozkurt B, et al. Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. Circ Heart Fail. 2020;13(3):e006513 .
- Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392(10152):1047-1057.
- Hannan AL, Harders MP, Hing W, Climstein M, Coombes JS, Furness J. Impact of wearable physical activity monitoring devices with exercise prescription or advice in the maintenance phase of cardiac rehabilitation: systematic review and meta-analysis. BMC Sports Sci Med Rehabil. 2019;11:14.
- McGregor G, Powell R, Begg B, et al. High-intensity interval training in cardiac rehabilitation: a multi-centre randomized controlled trial. Eur J Prev Cardiol. 2023;30(9):745-755.
- Cheng Q, Li F, Zhang Q, Yu H, Wang S. The Impact of Virtual Reality on Cardiopulmonary Function and Adherence in Cardiac Rehabilitation Patients: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2025;13(22):2969.
- ROMTech. PortableConnect® Adaptive Telemed Technology. Accessed September 19, 2026. https://romtech.com/portableconnect/
- ClinicalTrials.gov. ROMTech PortableConnect and Traditional Rehabilitation and CPM Device in Joint Pain and Knee Osteoarthritis. NCT04497129. Accessed September 19, 2026. https://clinicaltrials.gov/study/NCT04497129
- Cardiovascular Associates of America. Cardiovascular Associates of America and ROMTech Enter Multi-Year Partnership to Deliver Best-In-Class Home-Based Cardiac Rehabilitation Services to Patients. Accessed September 19, 2026. https://cvausa.com/news/cvausa-and-prospect-health-services-launch-innovative-value-based-care-partnership
- ClinicalTrials.gov. Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence. NCT05972070. Accessed September 19, 2026. https://clinicaltrials.gov/study/NCT05972070
- Blue Cross & Blue Shield of Rhode Island. Rehabilitative Devices with Remote Monitoring. Medical Coverage Policy. Providence, RI: BCBSRI; September 2024.
Article information
Authors
- W. Frank PeacockDepartment of Emergency Medicine, Baylor College of Medicine, Houston, Texas, USACorresponding author · [email protected]
How to cite
Peacock, W. F., 2026. New Frontiers in Cardiac Rehabilitation: Remote Delivery and Wearable Monitoring to Close a Global Participation Gap. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0685
Record
- Journal
- Medical Research Archives
- Issue
- Vol 14 No 10 (2026)
- Section
- Review Articles
- Published
- 31 October 2026
- ISSN
- 2375-1924
- Downloads
- 112
Copyright and licence
Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.